Test Price
1,000 AED✅ Home Collection Available
Irinotecan Toxicity Assessment (UGT1A1 Genotyping) / Gilbert Syndrome in UAE
Executive Summary & Core Metrics
✓ Diagnostic Accuracy: 99.9% Sensitivity via ISO 9001:2015 Accredited Sequencing
✓ Premium Logistics: ISO‑Certified Cold‑Chain Home Collection (VIP Mobile Phlebotomy 8 AM–11 PM)
✓ Clinical Guidance: Post‑Test Telephonic Clinical Correlation & Interpretation by DHA‑Licensed Experts
✓ Direct Insurance Billing Verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
The Irinotecan Toxicity Assessment (UGT1A1 Genotyping) precisely detects variants in the UGT1A1 gene that predict severe adverse reactions to irinotecan chemotherapy and diagnose Gilbert syndrome. In the UAE, this pharmacogenetic test empowers oncologists, gynecologic‑oncologists, and preventive medicine specialists to personalize dosage and avoid life‑threatening myelosuppression. Sanger sequencing covers all clinically relevant promoter and coding variants including UGT1A1*28, *6, and *60 alleles.
| Feature | Our Test (UGT1A1 Sequencing) | Typical Alternative (PCR Panel) |
|---|---|---|
| Methodology | Sanger Sequencing (Gold Standard) | Allele‑specific PCR (limited common variants) |
| Precision | 100% Specificity, detects rare and novel variants | Misses rare variants; lower sensitivity |
| TAT | 7–8 Days (Express possible) | 10–14 Days |
| Price | 1000 AED | Variable; often not all‑inclusive |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics at DNA Labs UAE, I emphasise that UGT1A1 genotyping must always be interpreted within the full clinical picture. While homozygosity for the *28 allele strongly predicts irinotecan-induced neutropenia, dose adjustment under oncologist supervision remains mandatory. Any patient with unexplained unconjugated hyperbilirubinemia or a family history of Gilbert syndrome would benefit from this test, but acute hepatic emergencies require immediate evaluation independent of genetic results.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠ Medication Advisory
Do not discontinue, alter, or self-adjust any prescribed medication, especially irinotecan or other chemotherapy agents, without direct consultation with your treating physician. This test informs clinical decisions but does not replace oncological judgment.
Exclusion Criteria & Urgent Red Flags
- This test is not indicated for acute abdominal emergency triage, routine pregnancy screening, or travel visa medical certificates.
- Not suitable for individuals who have received an allogeneic bone marrow transplant within the last 3 months due to donor DNA interference.
- If you experience sudden severe abdominal pain, high fever above 38.5°C, confusion, or bleeding, proceed directly to the nearest emergency department — do not wait for test results.
- Known diagnosis of Crigler‑Najjar syndrome type 1 requires evaluation via a different urgent clinical pathway.
Patient FAQ & Clinical Guidance
1. Is this test necessary before starting irinotecan chemotherapy?
Yes, UGT1A1 genotyping is essential to identify patients at risk of severe neutropenia and diarrhea from irinotecan. The U.S. FDA and ESMO guidelines recommend testing for the UGT1A1*28 allele prior to irinotecan administration. Poor metabolizers require a significant dose reduction to avoid life‑threatening toxicity. Our comprehensive sequencing covers all clinically relevant promoter and coding variants, ensuring no risk is missed.
2. Can this test confirm if I have Gilbert syndrome?
Yes, homozygosity for UGT1A1*28 (TA7/TA7) confirms Gilbert syndrome with greater than 99% accuracy, distinguishing benign hyperbilirubinemia from liver disease. Gilbert syndrome is a harmless condition causing intermittent mild jaundice, but genetic confirmation prevents unnecessary invasive procedures such as liver biopsy. Our assay also identifies compound heterozygous mutations for atypical presentations, providing definitive peace of mind.
3. How is the sample collected, and when will I receive my results?
Our certified phlebotomists collect a peripheral blood sample at your home within 8 AM–11 PM, and results are delivered in 7–8 days. Using ISO‑certified cold‑chain transport, the specimen reaches our DHA‑licensed laboratory in optimal condition. You will receive a detailed report with genotype interpretation, clinical recommendations, and a scheduled telephone consultation with a molecular geneticist.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our facility is ISO 9001:2015 certified and licensed by DHA and MOHAP. All telephonic guidance is provided by DHA‑licensed clinicians.
Clinical & Logistical Metadata
| Test Name | Irinotecan Toxicity Assessment (UGT1A1 Genotyping) / Gilbert Syndrome |
| Price (AED) | 1000 AED |
| Turnaround Time | 7–8 Days (Express option available) |
| Sample Type / Matrix | Peripheral Blood (EDTA tube) — VIP Mobile Phlebotomy and Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Sanger Sequencing (Gold Standard) — covers UGT1A1*28, *6, *60 and all coding variants |
| ICD-10-CM Code | Z13.89, E80.4 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians